Graft-versus-host disease is a complication of stem cell or bone marrow transplantation with few treatment options. But Mount Sinai researchers have been working on the problem for decades, bringing innovations to the field. With the latest grant renewal from the National Cancer Institute, a pair of clinical trials is primed to help researchers unveil biomarkers that will enable risk stratification and make inroads in addressing treatment resistance.
